Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CET
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at [email protected] and Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
11/21 BIOGEN : Appoints Jeff Capello as Executive Vice President and Chief Financial O..
11/20 BIOGEN : to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/02 BIOGEN : Appoints Chirfi Guindo as Executive Vice President and Head of Global M..
11/02 BIOGEN : Earnings Review and Free Research Report: Biogen’s Adjusted EPS Surged ..
11/02 BIOGEN : Presents New Data from Long-Term Extension of Phase 1b Study of Investi..
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
10/30 BIOGEN : to Present at the Clinical Trials on Alzheimer’s Disease Conferen..
10/27 BIOGEN : and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotec..
10/25 BIOGEN : Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-..
10/24 BIOGEN : Reports Quarterly Revenues of $3.1 Billion
More news
News from SeekingAlpha
08:33a YOUR DAILY PHARMA SCOOP : Exelixis Still Attractive, Portola's BevyxXa, Pluriste..
11/21 Understanding Aducanumab's Potential In Alzheimer's
11/21 New finance chief at Biogen
11/20 Tracking Jeffrey Ubben's ValueAct Portfolio - Q3 2017 Update
11/17 Denali Therapeutics Files To Raise $100 Million IPO
Financials ($)
Sales 2017 12 032 M
EBIT 2017 6 350 M
Net income 2017 3 890 M
Debt 2017 3 226 M
Yield 2017 -
P/E ratio 2017 16,88
P/E ratio 2018 14,32
EV / Sales 2017 5,71x
EV / Sales 2018 5,29x
Capitalization 65 516 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 359 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN18.26%65 516
CSL LIMITED43.07%49 706
ALEXION PHARMACEUTICALS-11.69%24 039
GRIFOLS SA33.08%18 690
BIOMARIN PHARMACEUTICAL0.18%14 575
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 794